Details of the Drug Combination

General Information of Drug Combination (ID: DCBIA53)

Drug Combination Name

Indazole derivative 5 Taxol

Indication

Disease Entry	Status	REF
Astrocytoma	Investigative	[1]

Component Drugs

Indazole derivative 5 DMM1I8R

Taxol DMUOT9V

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: U251

Zero Interaction Potency (ZIP) Score: 6.27

Bliss Independence Score: 7.38

Loewe Additivity Score: 8.16

LHighest Single Agent (HSA) Score: 9.83

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[6]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[6]
------------------------------------------------------------------------------------

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pancreatic cancer	2C10	Phase 3	[4]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[2]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DCHDEOI	MOLT-4	Investigative	[1]
Anaplastic large cell lymphoma	DC1BPVF	SR	Investigative	[1]
Astrocytoma	DC85OCH	SNB-19	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DCI2YLE	CCRF-CEM	Investigative	[1]
Glioma	DCZAYAR	SF-539	Investigative	[1]
Colon carcinoma	DC8RCVM	KM12	Investigative	[7]
Adenocarcinoma	DC1KST3	A549	Investigative	[8]
Adenocarcinoma	DCUHXAD	HCC-2998	Investigative	[8]
Adenocarcinoma	DC33V27	HCT-15	Investigative	[8]
Amelanotic melanoma	DCRFBF0	MDA-MB-435	Investigative	[8]
Malignant melanoma	DCJJQDP	UACC62	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
7	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
8	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.